Loading...
Market
FTC requires divestitures for Catalent acquisition approval by 2024
4
Resolution / Starting Odds
Yes • 50%
No • 50%
FTC press release or major financial news outlets
Story
FTC Extends Review of Novo Holdings' $16.5 Billion Catalent Acquisition
May 3, 2024, 03:05 PM
The U.S. Federal Trade Commission (FTC) has issued a second request for more information regarding the $16.5 billion acquisition of Catalent by Novo Nordisk's parent company, Novo Holdings. This move, part of an extended antitrust review, could delay the deal by an additional 30 days. The request reflects the FTC's ongoing scrutiny of the transaction amid concerns from other pharmaceutical groups and contract manufacturers.
View original story
Similar markets
Divestiture of assets • 25%
Restrictions on future acquisitions • 25%
Cap on market share • 25%
No significant conditions • 25%
